


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

1 - 20. (canceled)

21. (currently amended) A method for the therapeutic therapy of colorectal cancer, ~~prostate cancer~~, small cell lung cancer, non-small cell lung cancer, breast cancer, ~~pancreatic cancer~~, renal cancer, or gastric cancer, ~~bladder cancer or ovarian cancer~~ comprising administering to a patient suffering therefrom a pharmaceutically effective amount of a compound of formula I



(I)

or a pharmaceutically acceptable salt or prodrug thereof:

wherein Q is (CH₂)_m(CH(R¹))_n(CH₂)_p;

n is 0 or 1;

m and p are, independently, 0, 1 or 2;

R¹ is hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl or C₃₋₆ alkynyl;

R² is hydrogen, halogen, C₁₋₆ alkyl optionally substituted by hydroxy or C₁₋₆ alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen, C₁₋₆ alkyl, CF₃, OCF₃, OR⁶, CN and methylenedioxy;

R³, R⁴ and R⁵ are, independently, hydrogen, halogen, C₁₋₆ alkyl optionally substituted by hydroxy or C₁₋₆ alkoxy, CF₃, OR⁶, COR⁷, NHCOR⁸, NHCONHR⁸, NHSO₂R⁸, CONHR⁹, CN, SO₂R⁸ or NR¹⁰R¹¹;

R⁶ is hydrogen, C₂₋₆ alkenyl, C₃₋₆ alkynyl, C₁₋₆ alkyl optionally substituted by hydroxy or C₁₋₆ alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF₃, OCF₃, CN, C₁₋₆ alkyl, C₁₋₆ alkoxy and methylenedioxy;

R⁷ is C₁₋₆ alkyl, OR⁶ or phenyl optionally substituted by one or more substituents selected from halogen, CF₃, OCF₃, CN, C₁₋₆ alkyl, C₁₋₆ alkoxy and NHCOR⁸;

R⁸ is C₁₋₆ alkyl, C₂₋₆ alkenyl, or C₁₋₆ alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF₃, OCF₃, OR⁶, CN, C₁₋₆ alkyl, methylenedioxy and NR¹⁰R¹¹; C₃₋₆ cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from NR¹², S and O; or aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF₃, OCF₃, OR⁶, CN, C₁₋₆ alkyl, methylenedioxy and NR¹⁰R¹¹;

R⁹ is C₁₋₆ alkyl, C₁₋₆ alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally

substituted by one or more substituents selected from halogen, C₁₋₆ alkyl, CF₃, OCF₃, CN, C₁₋₆ alkoxy and methylenedioxy;

R¹⁰ and R¹¹ are, independently, hydrogen or C₁₋₆ alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from NR¹², O and S; and R¹² is hydrogen or C₁₋₆ alkyl.

22 - 27. (canceled)